Circular Genomics
Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predicts whether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health.
Domain
circulargenomics.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$15.0M
Founded
2020
Tech Stack (21 technologies)
Frequently Asked Questions
What technologies does Circular Genomics use?+
Circular Genomics uses 21 technologies including Google Analytics, Google Tag Manager, HubSpot.
What industry is Circular Genomics in?+
Circular Genomics operates in the Biotechnology industry.
Where is Circular Genomics based?+
Circular Genomics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026